Skip to content

Screening and therapeutic monitoring of multiple myeloma by MALDI-TOF MS analysis

Screening and therapeutic monitoring of multiple myeloma by MALDI-TOF MS analysis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066423
Enrollment
Unknown
Registered
2022-12-05
Start date
2022-12-06
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

Control group:N/A

Sponsors

Zhujiang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Inclusion criteria for cases: Serum samples from related people diagnosed with multiple myeloma were included in MALDI-TOF-MS analysis by serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (IFE), Ig isotype detection and other methods. (2) Inclusion criteria of the controls were as follows: individuals in good health without obvious disease and with normal physical examination report; Avoid people who have not suffered from major chronic diseases in recent years, such as hypertension, diabetes, chronic kidney disease, etc; controls were appropriately selected that matched cases for age and sex.

Exclusion criteria

Exclusion criteria: Common exclusion criteria for cases and control were as follows: samples with incomplete sample information and untraceable source; Samples whose sample volume is insufficient for testing; Samples that do not meet the requirements for sample collection and storage.

Design outcomes

Primary

MeasureTime frame
M-protein;

Countries

China

Contacts

Public ContactHongwei Zhou

Zhujiang Hospital of Southern Medical University

hzhou@smu.edu.cn+86 18688489622

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026